<DOC>
	<DOC>NCT01556997</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and efficacy of a fixed-dose combination drug compared to two other drugs (monotherapies) in controlling hypertension.</brief_summary>
	<brief_title>Perindopril Amlodipine for the Treatment of Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Perindopril</mesh_term>
	<criteria>Essential hypertension For female subjects, a negative serum pregnancy test Ability to provide written informed consent Night shift workers whose work hours include midnight to 4:00 a.m. Secondary hypertension An arm size that precludes the use of the digital blood pressure monitor cuff (arm size &gt; 42 cm) Renal dysfunction, severe renal impairment, bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, subjects with only 1 kidney, or postrenal transplant subjects Female subjects who are pregnant, planning to become pregnant History of malignancy within 5 years Primary aldosteronism Heart failure (NYHA functional class 34), hypertrophic obstructive cardiomyopathy, or hemodynamically relevant stenosis of the aortic or mitral valve Significant cardiac arrhythmias, MI, stroke, CABG, PTCA, unstable angina Known hypersensitivity to any component of the study drugs Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Essential Hypertension</keyword>
</DOC>